Cargando…
Plasma Nogo-A and placental growth factor levels are associated with portal hypertension in patients with liver cirrhosis
BACKGROUND: Clinically significant portal hypertension (CSPH) and severe portal hypertension (SPH) increase the risk for decompensation and life-threatening complications in liver cirrhosis. Pathologic angiogenesis might contribute to the formation of these conditions. Placental growth factor (PlGF)...
Autores principales: | , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Baishideng Publishing Group Inc
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6589742/ https://www.ncbi.nlm.nih.gov/pubmed/31249451 http://dx.doi.org/10.3748/wjg.v25.i23.2935 |
_version_ | 1783429433652150272 |
---|---|
author | Gelman, Sigita Salteniene, Violeta Pranculis, Andrius Skieceviciene, Jurgita Zykus, Romanas Petrauskas, Dalius Kupcinskas, Limas Canbay, Ali Link, Alexander Kupcinskas, Juozas |
author_facet | Gelman, Sigita Salteniene, Violeta Pranculis, Andrius Skieceviciene, Jurgita Zykus, Romanas Petrauskas, Dalius Kupcinskas, Limas Canbay, Ali Link, Alexander Kupcinskas, Juozas |
author_sort | Gelman, Sigita |
collection | PubMed |
description | BACKGROUND: Clinically significant portal hypertension (CSPH) and severe portal hypertension (SPH) increase the risk for decompensation and life-threatening complications in liver cirrhosis. Pathologic angiogenesis might contribute to the formation of these conditions. Placental growth factor (PlGF) and Nogo-A protein are biomarkers of pathological angiogenesis, but data on their role in liver cirrhosis and portal hypertension is scarce. AIM: To determine plasma levels of PlGF and Nogo-A in patients with liver cirrhosis, CSPH, SPH and potential to predict portal hypertension. METHODS: A cohort of 122 patients with hepatitis C virus and/or alcohol-induced liver cirrhosis with characterized hepatic venous pressure gradient (HVPG) were included in the study. Demographic data, medical history, Child-Turcotte-Pugh and Model of End Stage liver disease score, clinical chemistry, liver stiffness values were recorded on the day of the procedure prior HVPG measurement. The degree of portal hypertension was determined by the invasive HVPG measurement. Nogo-A and PlGF plasma levels were evaluated using enzyme linked immunosorbent assay. The control group consisted of 30 healthy age- and sex- matched individuals. RESULTS: Peripheral PlGF levels were higher and Nogo-A levels were lower in patients with liver cirrhosis (23.20 vs 9.85; P < 0.0001 and 2.19 vs 3.12; P = 0.004 respectively). There was a positive linear correlation between peripheral levels of PlGF and HVPG (r = 0.338, P = 0.001) and negative linear correlation between the peripheral Nogo-A levels and HVPG (r = -0.267, P = 0.007). PlGF levels were higher in CSPH and SPH (P = 0.006; P < 0.0001) whereas Nogo-A levels were lower (P = 0.01; P < 0.033). Area under the curve for the diagnosis of CSPH for PlGF was 0.68 (P = 0.003) and for Nogo-A - 0.67 (P = 0.01); for SPH 0.714 (P < 0.0001) and 0.65 (P = 0.014) respectively. PlGF levels were higher and Nogo-A levels were lower in patients with esophageal varices (P < 0.05). PlGF cut-off value of 25 pg/mL distinguished patients with CSPH at 55.7% sensitivity and 76.7% specificity; whereas Nogo-A cut-off value of 1.12 ng/mL was highly specific (93.1%) for the diagnosis of CSPH. CONCLUSION: Plasma PlGF levels were higher while Nogo-A levels were lower in patients with liver cirrhosis and portal hypertension. Biomarkers showed moderate predictive value in determining CSPH and SPH. |
format | Online Article Text |
id | pubmed-6589742 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2019 |
publisher | Baishideng Publishing Group Inc |
record_format | MEDLINE/PubMed |
spelling | pubmed-65897422019-06-27 Plasma Nogo-A and placental growth factor levels are associated with portal hypertension in patients with liver cirrhosis Gelman, Sigita Salteniene, Violeta Pranculis, Andrius Skieceviciene, Jurgita Zykus, Romanas Petrauskas, Dalius Kupcinskas, Limas Canbay, Ali Link, Alexander Kupcinskas, Juozas World J Gastroenterol Case Control Study BACKGROUND: Clinically significant portal hypertension (CSPH) and severe portal hypertension (SPH) increase the risk for decompensation and life-threatening complications in liver cirrhosis. Pathologic angiogenesis might contribute to the formation of these conditions. Placental growth factor (PlGF) and Nogo-A protein are biomarkers of pathological angiogenesis, but data on their role in liver cirrhosis and portal hypertension is scarce. AIM: To determine plasma levels of PlGF and Nogo-A in patients with liver cirrhosis, CSPH, SPH and potential to predict portal hypertension. METHODS: A cohort of 122 patients with hepatitis C virus and/or alcohol-induced liver cirrhosis with characterized hepatic venous pressure gradient (HVPG) were included in the study. Demographic data, medical history, Child-Turcotte-Pugh and Model of End Stage liver disease score, clinical chemistry, liver stiffness values were recorded on the day of the procedure prior HVPG measurement. The degree of portal hypertension was determined by the invasive HVPG measurement. Nogo-A and PlGF plasma levels were evaluated using enzyme linked immunosorbent assay. The control group consisted of 30 healthy age- and sex- matched individuals. RESULTS: Peripheral PlGF levels were higher and Nogo-A levels were lower in patients with liver cirrhosis (23.20 vs 9.85; P < 0.0001 and 2.19 vs 3.12; P = 0.004 respectively). There was a positive linear correlation between peripheral levels of PlGF and HVPG (r = 0.338, P = 0.001) and negative linear correlation between the peripheral Nogo-A levels and HVPG (r = -0.267, P = 0.007). PlGF levels were higher in CSPH and SPH (P = 0.006; P < 0.0001) whereas Nogo-A levels were lower (P = 0.01; P < 0.033). Area under the curve for the diagnosis of CSPH for PlGF was 0.68 (P = 0.003) and for Nogo-A - 0.67 (P = 0.01); for SPH 0.714 (P < 0.0001) and 0.65 (P = 0.014) respectively. PlGF levels were higher and Nogo-A levels were lower in patients with esophageal varices (P < 0.05). PlGF cut-off value of 25 pg/mL distinguished patients with CSPH at 55.7% sensitivity and 76.7% specificity; whereas Nogo-A cut-off value of 1.12 ng/mL was highly specific (93.1%) for the diagnosis of CSPH. CONCLUSION: Plasma PlGF levels were higher while Nogo-A levels were lower in patients with liver cirrhosis and portal hypertension. Biomarkers showed moderate predictive value in determining CSPH and SPH. Baishideng Publishing Group Inc 2019-06-21 2019-06-21 /pmc/articles/PMC6589742/ /pubmed/31249451 http://dx.doi.org/10.3748/wjg.v25.i23.2935 Text en ©The Author(s) 2019. Published by Baishideng Publishing Group Inc. All rights reserved. http://creativecommons.org/licenses/by-nc/4.0/ This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. |
spellingShingle | Case Control Study Gelman, Sigita Salteniene, Violeta Pranculis, Andrius Skieceviciene, Jurgita Zykus, Romanas Petrauskas, Dalius Kupcinskas, Limas Canbay, Ali Link, Alexander Kupcinskas, Juozas Plasma Nogo-A and placental growth factor levels are associated with portal hypertension in patients with liver cirrhosis |
title | Plasma Nogo-A and placental growth factor levels are associated with portal hypertension in patients with liver cirrhosis |
title_full | Plasma Nogo-A and placental growth factor levels are associated with portal hypertension in patients with liver cirrhosis |
title_fullStr | Plasma Nogo-A and placental growth factor levels are associated with portal hypertension in patients with liver cirrhosis |
title_full_unstemmed | Plasma Nogo-A and placental growth factor levels are associated with portal hypertension in patients with liver cirrhosis |
title_short | Plasma Nogo-A and placental growth factor levels are associated with portal hypertension in patients with liver cirrhosis |
title_sort | plasma nogo-a and placental growth factor levels are associated with portal hypertension in patients with liver cirrhosis |
topic | Case Control Study |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6589742/ https://www.ncbi.nlm.nih.gov/pubmed/31249451 http://dx.doi.org/10.3748/wjg.v25.i23.2935 |
work_keys_str_mv | AT gelmansigita plasmanogoaandplacentalgrowthfactorlevelsareassociatedwithportalhypertensioninpatientswithlivercirrhosis AT saltenienevioleta plasmanogoaandplacentalgrowthfactorlevelsareassociatedwithportalhypertensioninpatientswithlivercirrhosis AT pranculisandrius plasmanogoaandplacentalgrowthfactorlevelsareassociatedwithportalhypertensioninpatientswithlivercirrhosis AT skiecevicienejurgita plasmanogoaandplacentalgrowthfactorlevelsareassociatedwithportalhypertensioninpatientswithlivercirrhosis AT zykusromanas plasmanogoaandplacentalgrowthfactorlevelsareassociatedwithportalhypertensioninpatientswithlivercirrhosis AT petrauskasdalius plasmanogoaandplacentalgrowthfactorlevelsareassociatedwithportalhypertensioninpatientswithlivercirrhosis AT kupcinskaslimas plasmanogoaandplacentalgrowthfactorlevelsareassociatedwithportalhypertensioninpatientswithlivercirrhosis AT canbayali plasmanogoaandplacentalgrowthfactorlevelsareassociatedwithportalhypertensioninpatientswithlivercirrhosis AT linkalexander plasmanogoaandplacentalgrowthfactorlevelsareassociatedwithportalhypertensioninpatientswithlivercirrhosis AT kupcinskasjuozas plasmanogoaandplacentalgrowthfactorlevelsareassociatedwithportalhypertensioninpatientswithlivercirrhosis |